Krystal Biotech Inc. develops and commercializes pharmaceutical products for patients suffering from dermatological diseases. The company’s lead product candidate includes KB103, which is in preclinical studies to treat dystrophic epidermolysis bullosa, a genetic disease. The company was founded in 2015 and is based in Pittsburgh, Pennsylvania.
Today, in a regulatory filing, Krystal Biotech ([[KRYS]] +1.6%) disclosed the key milestones expected for the company’s pipeline in the year ahead. The timeline includes four data readouts, one trial initiation, and a possible IND filing.With topline data expected in 2H 2021, the pivotal Phase 3 (GEM-3) trial stands out from the...
PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases today announced the appointment of Chris Mason, MD, PhD, FRCS, FMedSci, and Jing L. Marantz, MD, PhD, MBA to its board of directors. “We are pleased to welcome Drs. Mason and Marantz to our board of directors,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech, Inc. “They bring significant gene therapy translational and rare diseas
PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in non-invasive, redosable gene therapies, today announced that Krish S. Krishnan, chairman and chief executive officer will be participating in a fireside chat at the Evercore ISI 3rd Annual HealthCONx virtual conference taking place December 1-3, 2020. Details for the webcast are as follows: Evercore ISI 3rd Annual HealthCONx virtual conference Presentation Date: Tuesday, December 1, 2020 Presentation Ti